4,069 Shares in Novartis AG (NYSE:NVS) Acquired by Nwam LLC

Nwam LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,069 shares of the company’s stock, valued at approximately $468,000.

Other hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in shares of Novartis by 28.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,492 shares of the company’s stock valued at $435,000 after acquiring an additional 1,004 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Novartis by 3.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 115,849 shares of the company’s stock worth $11,207,000 after purchasing an additional 3,696 shares during the last quarter. Silvercrest Asset Management Group LLC increased its position in Novartis by 4.8% during the first quarter. Silvercrest Asset Management Group LLC now owns 10,994 shares of the company’s stock worth $1,063,000 after purchasing an additional 500 shares during the last quarter. Bayesian Capital Management LP purchased a new position in Novartis during the first quarter worth about $1,025,000. Finally, Janus Henderson Group PLC boosted its stake in Novartis by 0.6% during the first quarter. Janus Henderson Group PLC now owns 2,568,728 shares of the company’s stock worth $248,473,000 after buying an additional 16,015 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $121.00 target price (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. Bank of America downgraded shares of Novartis from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $135.00 to $130.00 in a research note on Wednesday, September 11th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Jefferies Financial Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. Finally, BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $121.50.

Novartis Stock Up 0.4 %

NVS stock opened at $104.28 on Monday. The company’s 50 day moving average is $111.87 and its two-hundred day moving average is $110.20. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The stock has a market cap of $213.15 billion, a P/E ratio of 12.11, a PEG ratio of 1.49 and a beta of 0.58. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the prior year, the firm earned $1.74 EPS. Research analysts expect that Novartis AG will post 7.66 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.